Andrew Yule & Company Ltd
ANDREWYUAndrew Yule & Company Ltd is strength at full price. The numbers are improving — and a P/E at the 86th percentile of its own range says the market knows.
The sharpest disagreement: profits are rising, but only 43% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (12 weeks in) while the P/E sits at the 86th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit −111.6% year on year, and 43% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Andrew Yule & Company Ltd trades at ₹26.1, in a confirmed uptrend and 12 weeks into that stage. That is +2.1% against its own 200-day average. It sits at 69% of a 52-week range of ₹17 to ₹30. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a confirmed uptrend — week 12 of stage 2, confirmed. At ₹26.1 it trades +2.1% versus its 200-day average and sits at 69% of its 52-week range (₹17–₹30).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +19% while the NIFTY 500 moved +267% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-09-04) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Andrew Yule & Company Ltd trades at 121.6× P/E, at the pricey end of its own range (86th percentile). Its long-run median P/E is 52.7×, measured across 10.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 121.6× is at the pricey end of its own range (86th percentile), against a long-run median of 52.7× measured over 10.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
The price move, decomposed: over 5y, of the +1.0%/yr price move, ~−13.8%/yr came from earnings growth and ~+14.8 pp from the multiple (expanding); over 10y, of the +2.2%/yr price move, ~−17.2%/yr came from earnings growth and ~+19.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Andrew Yule & Company Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −5.1% | −7.6% | −2.2% | −2.6% |
| Share price | −1.5% | −5.0% | +1.0% | +2.2% |
4-Factor Sector Score
36.1/100 — rank 14 of 20 in Diversified · 66% evidence confidence
Andrew Yule & Company Ltd scores 36.1 out of 100 against the 20 companies it is compared with in Diversified, ranking 14. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 14.9 + 3.7 + 10 + 7.5 = 36.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Andrew Yule & Company Ltd reported ₹58.3 Cr of revenue in the Jun 26 quarter, +3.8% year on year. Over 10 years it has compounded at −2.6% a year. The last full year, FY26, came in at ₹295 Cr. The last four reported quarters add to ₹298 Cr.
FY26 revenue came in at ₹295 Cr (−5.1% on the year), capping 10 years at −2.6% compound. The latest quarter (Jun 26) printed ₹58.3 Cr, +3.8% year on year.
Pace check: the last four quarters averaged −3.1% growth against the decade's −2.6% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −4.8% over the last 4 quarters against −1.5%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Andrew Yule & Company Ltd's operating margin is −23.4% in the Jun 26 quarter, +25.9 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −32.0% to 8.0%. The current quarter sits inside that band.
The latest quarter's operating margin is −23.4%, +25.9 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −32.0%–8.0%.
Why the margin moved: operating margin went +25.9 pp year on year while gross margin went +23.4 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Andrew Yule & Company Ltd posted a net loss of ₹2.3 Cr in the Jun 26 quarter. The full FY26 year was a loss of ₹19.0 Cr. That loss is 4.0% of the quarter's revenue. The same quarter a year earlier earned ₹20.1 Cr. 10 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹−2.3 Cr, −111.6% year on year. On the full year, FY26 printed ₹−19.0 Cr (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 43% of Andrew Yule & Company Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−80.0 Cr of operating cash against ₹−19.0 Cr of profit. After ₹20.0 Cr of capital spending, ₹−100 Cr was left as free cash.
FY26: operating cash of ₹−80.0 Cr against reported profit of ₹−19.0 Cr, leaving free cash of ₹−100 Cr after ₹20.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 43% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 43%: the cash cycle stretched 33 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 33 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Andrew Yule & Company Ltd's cash conversion cycle runs 35 days in FY26, up from 2 days in FY21. Capital spending ran ₹51.0 Cr over the last 3 years. At FY26 sales of ₹295 Cr each day of that cycle holds about ₹0.8 Cr, so roughly ₹28.0 Cr sits inside the business at any moment.
FY26: debtors at 108 days, inventory at 166 days — roughly 5.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 35 days, looser than FY21's 2.
The full loop: cash goes out to suppliers and production on day 0; stock waits 166 days to sell; customers pay about 108 days after that; and suppliers themselves are paid at 239 days — netting out to the 35-day cycle.
In money terms: at FY26 sales of ₹295 Cr, each day of the cycle holds about ₹0.8 Cr — so the 35-day loop keeps roughly ₹28.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹51.0 Cr over the last 3 fiscal years against ₹35.0 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹45.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Andrew Yule & Company Ltd earns a ROCE of −6% in FY26. That is up from a trough of −14% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is −6.4% net margin on 0.39× asset turns.
FY26 ROCE is −6%, recovered from a FY24 trough of −14% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): −6.4% net margin × 0.39× asset turns × 2.30× balance-sheet leverage ≈ −5.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Andrew Yule & Company Ltd carries ₹121 Cr of borrowings against ₹326 Cr of equity in FY26, a debt-to-equity of 0.37. Operating profit covers the interest bill −13×. Over 5 years borrowings went from ₹70.0 Cr to ₹121 Cr. Capital spending ran ₹51.0 Cr across the last 3 of those years.
FY26: borrowings of ₹121 Cr against equity of ₹326 Cr — a debt-to-equity of 0.37. Operating profit covers the interest bill −13×. Over 5 years borrowings went from ₹70.0 Cr to ₹121 Cr while capital spending ran ₹51.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Andrew Yule & Company Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved +0.0 points over the same window, to 0.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +0.0 points over 8 quarters to 89.3%; Foreign institutions: +0.0 points over 8 quarters to 0.0%; Domestic institutions: +0.0 points over 8 quarters to 2.2%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Andrew Yule & Company Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Sobhagya Mercantile Ltd512014 | 62.8/100Mixed-positive evidence75% evidence | BREAKING OUT | 15.9/35 Revenue 21.9% · PAT 8.1% · OPM change -0.5 pp 95% evidence | 19.1/25 ROCE 23.4% · OPM 14.4% 76% evidence | 9.3/20 P/E 70.7× · PEG — 15% evidence | 18.5/20 RS sector 45.9% · RS bench 52.9% · 1Y 54.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 19.1 + 9.3 + 18.5 = 62.8 · Decision use: Price leads the evidence: RS versus the benchmark is 52.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 2Kalind Ltd526935 | 60.5/100Mixed-positive evidence82% evidence | 30.6/35 Revenue 100% · PAT 100% · OPM change 21 pp 95% evidence | 18.2/25 ROCE 32% · OPM 63% 76% evidence | 11.1/20 P/E 13.9× · PEG — 50% evidence | 0.6/20 RS sector -89.7% · RS bench -36.7% · 1Y -77%0 of 8 weeks ahead to 2026-08-16 100% evidence | |
| Exact sum: 30.6 + 18.2 + 11.1 + 0.6 = 60.5 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -89.7% and the one-year return is -77%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Grasim Industries LtdGRASIM | 60.0/100Mixed-positive evidence82% evidence | LEADER | 24.3/35 Revenue 19.5% · PAT 33.1% · OPM change 1 pp 95% evidence | 13.1/25 ROCE 8% · OPM 23% 76% evidence | 6.8/20 P/E 38.9× · PEG — 50% evidence | 15.8/20 RS sector 8.6% · RS bench 14% · 1Y 17%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 13.1 + 6.8 + 15.8 = 60 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4BCL Industries LtdBCLIND | 57.1/100Mixed-positive evidence87% evidence | ASLEEP | 20.1/35 Revenue -13.1% · PAT 15.2% · OPM change 3 pp 95% evidence | 14.9/25 ROCE 13.9% · OPM 10% 95% evidence | 13.1/20 P/E 8.7× · PEG — 50% evidence | 9.0/20 RS sector -2.8% · RS bench 2% · 1Y -15.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 14.9 + 13.1 + 9 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Indiabulls LimitedIBULLSLTD | 56.0/100Mixed-positive evidence67% evidence | LEADER | 18.4/35 Revenue 100% · PAT 100% · OPM change 28 pp 71% evidence | 14.1/25 ROCE 16.2% · OPM 43% 76% evidence | 10.6/20 P/E 12.6× · PEG — 15% evidence | 12.9/20 RS sector 33.2% · RS bench 38.6% · 1Y 34.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 14.1 + 10.6 + 12.9 = 56 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Balmer Lawrie & Company LtdBALMLAWRIE | 54.3/100Mixed-positive evidence82% evidence | BASING | 17.1/35 Revenue 8.9% · PAT 3.8% · OPM change 1 pp 95% evidence | 15.1/25 ROCE 14.6% · OPM 13% 76% evidence | 14.5/20 P/E 10.3× · PEG — 50% evidence | 7.6/20 RS sector -10.7% · RS bench -6.1% · 1Y -25.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 15.1 + 14.5 + 7.6 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Nurture Well Industries Ltd531889 | 52.6/100Mixed-positive evidence75% evidence | TURNING | 19.8/35 Revenue 34% · PAT 27% · OPM change 1 pp 95% evidence | 16.5/25 ROCE 22.9% · OPM 11% 76% evidence | 11.5/20 P/E 8.4× · PEG — 15% evidence | 4.8/20 RS sector -33.6% · RS bench -29.8% · 1Y 14.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 16.5 + 11.5 + 4.8 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Texmaco Infrastructure & Holdings LtdTEXINFRA | 51.9/100Mixed-positive evidence80% evidence | LEADER | 18.9/35 Revenue 5.5% · PAT 100% · OPM change -37.9 pp 95% evidence | 7.4/25 ROCE 1.4% · OPM -48.8% 95% evidence | 8.5/20 P/E 162× · PEG — 15% evidence | 17.1/20 RS sector 10% · RS bench 15.5% · 1Y 22.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 7.4 + 8.5 + 17.1 = 51.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 93M India Ltd3MINDIA | 51.2/100Mixed-positive evidence94% evidence | FADING | 21.9/35 Revenue 15.7% · PAT 16.1% · OPM change -3 pp 100% evidence | 18.7/25 ROCE 50% · OPM 17% 100% evidence | 1.8/20 P/E 83.6× · PEG 3.29 100% evidence | 8.8/20 RS sector -3.7% · RS bench -0.7% · 1Y 7.7%4 of 10 weeks ahead 70% evidence |
| Exact sum: 21.9 + 18.7 + 1.8 + 8.8 = 51.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 10Bluspring Enterprises LtdBLUSPRING | 44.0/100Thin evidence · provisional57% evidence | BREAKING OUT | 18.8/35 Revenue 11.8% · PAT 90.6% · OPM change 0.7 pp 71% evidence | 4.2/25 ROCE 5.2% · OPM 2.2% 95% evidence | 8.7/20 P/E 130× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 65.6% · 1Y 63.2%10 of 10 weeks ahead 25% evidence |
| Exact sum: 18.8 + 4.2 + 8.7 + 12.3 = 44 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Nava LtdNAVA | 42.4/100Mixed-negative evidence93% evidence | BASING | 10.0/35 Revenue 9% · PAT -29.9% · OPM change -6 pp 100% evidence | 13.1/25 ROCE 12.8% · OPM 43% 100% evidence | 12.9/20 P/E 20.6× · PEG 1.16 65% evidence | 6.4/20 RS sector -9.8% · RS bench -5.3% · 1Y -18.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10 + 13.1 + 12.9 + 6.4 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Tube Investments of India LtdTIINDIA | 37.5/100Mixed-negative evidence100% evidence | ASLEEP | 15.6/35 Revenue 17.6% · PAT 6.6% · OPM change -1 pp 100% evidence | 15.4/25 ROCE 17.1% · OPM 9% 100% evidence | 3.0/20 P/E 80.5× · PEG 9.63 100% evidence | 3.5/20 RS sector -10.7% · RS bench -6.2% · 1Y -12.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 15.4 + 3 + 3.5 = 37.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Bharat Global Developers LtdBGDL | 37.4/100Mixed-negative evidence63% evidence | 8.2/35 Revenue -80% · PAT -80% · OPM change 4.2 pp 95% evidence | 7.2/25 ROCE 0% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.0/20 RS sector 165.8% · RS bench -36.8% · 1Y -47.4%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 8.2 + 7.2 + 10 + 12 = 37.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Andrew Yule & Company Ltdthis pageANDREWYU | 36.1/100Mixed-negative evidence66% evidence | TURNING | 14.9/35 Revenue -4.8% · PAT -80% · OPM change 25.9 pp 95% evidence | 3.7/25 ROCE -6.3% · OPM -23.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.5/20 RS sector -37% · RS bench 9.7% · 1Y -1.1%6 of 11 weeks ahead 70% evidence |
| Exact sum: 14.9 + 3.7 + 10 + 7.5 = 36.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Kesar Enterprises LtdKESAR | 35.0/100Thin evidence · provisional51% evidence | 14.4/35 Revenue -9% · PAT 34.7% · OPM change -22132 pp 62% evidence | 4.9/25 ROCE -19.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.7/20 RS sector -44.4% · RS bench 0% · 1Y -39.1%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 14.4 + 4.9 + 10 + 5.7 = 35 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Swan Corp LtdSWANCORP | 29.0/100Adverse evidence69% evidence | BASING | 8.7/35 Revenue -16.7% · PAT -67.2% · OPM change -2.6 pp 95% evidence | 5.7/25 ROCE -0.6% · OPM -0.4% 76% evidence | 9.8/20 P/E 41.6× · PEG — 15% evidence | 4.8/20 RS sector -29.3% · RS bench -20.1% · 1Y -34.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 8.7 + 5.7 + 9.8 + 4.8 = 29 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Integrated Industries LtdIIL | 63.8/100Thin evidence · provisional50% evidence | 20.5/35 Revenue 60.5% · PAT 94.6% · OPM change 2 pp 53% evidence | 16.4/25 ROCE 30.5% · OPM 11% 57% evidence | 10.9/20 P/E 11.6× · PEG — 15% evidence | 16.0/20 RS sector 51.9% · RS bench 63.7% · 1Y 136.8%11 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 20.5 + 16.4 + 10.9 + 16 = 63.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Arunis Abode LtdARUNIS | 50.8/100Thin evidence · provisional45% evidence | 15.2/35 Revenue 100% · PAT 100% · OPM change -17.7 pp 40% evidence | 9.5/25 ROCE -5.3% · OPM 28.5% 57% evidence | 9.4/20 P/E 62.5× · PEG — 15% evidence | 16.7/20 RS sector 131.3% · RS bench 136.7% · 1Y 224%12 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 15.2 + 9.5 + 9.4 + 16.7 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Piramal Enterprises Ltd(Merged)PEL | 45.1/100Thin evidence · provisional41% evidence | 16.7/35 Revenue -35.5% · PAT 100% · OPM change -9.8 pp 27% evidence | 11.1/25 ROCE 4.9% · OPM 77.4% 57% evidence | 9.6/20 P/E 61.4× · PEG — 15% evidence | 7.7/20 RS sector -20.3% · RS bench 1% · 1Y 3.7%6 of 12 weeks ahead to 2025-09-24 70% evidence | |
| Exact sum: 16.7 + 11.1 + 9.6 + 7.7 = 45.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Rossell India LtdROSSELLIND | 42.6/100Thin evidence · provisional47% evidence | 14.8/35 Revenue 4.8% · PAT -41.1% · OPM change 0.1 pp 36% evidence | 11.7/25 ROCE 6.4% · OPM 10.7% 71% evidence | 10.8/20 P/E 11.8× · PEG — 15% evidence | 5.3/20 RS sector -28.8% · RS bench -19.6% · 1Y -32%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 14.8 + 11.7 + 10.8 + 5.3 = 42.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Andrew Yule & Company Ltd's share price today?
Andrew Yule & Company Ltd trades at ₹26.1, −1.5% over the past year. The company is valued at ₹1,283 Cr. The stock sits at 69% of its 52-week range of ₹17–₹30, +2.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 12 weeks in. — as of 11 September 2026.
What were Andrew Yule & Company Ltd's latest quarterly results?
Andrew Yule & Company Ltd reported revenue of ₹58.3 Cr and a net loss of ₹2.3 Cr for the Jun 26 quarter. Revenue rose 3.8% and profit fell 111.6% year on year. Earnings per share were ₹−0.05. The operating margin was −23.4%, 25.9 pp higher than a year earlier. — as of 11 September 2026.
What is Andrew Yule & Company Ltd's revenue?
Andrew Yule & Company Ltd reported revenue of ₹58.3 Cr in the Jun 26 quarter, +3.8% year on year. For the full FY26 fiscal year, revenue was ₹295 Cr (−5.1%). Over the last 10 years revenue compounded at −2.6% a year. — as of 11 September 2026.
What is Andrew Yule & Company Ltd's profit?
Andrew Yule & Company Ltd earned ₹−2.3 Cr of net profit in the Jun 26 quarter, −111.6% year on year. Full-year FY26 profit was ₹−19.0 Cr. The operating margin ran −23.4% in the latest quarter. — as of 11 September 2026.
What is Andrew Yule & Company Ltd's market cap?
Andrew Yule & Company Ltd's market capitalisation is ₹1,283 Cr at a share price of ₹26.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Andrew Yule & Company Ltd's P/E ratio?
Andrew Yule & Company Ltd trades at a P/E of 121.6×, at the 86th percentile of its own 10-year range, against a long-run median of 52.7×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Andrew Yule & Company Ltd pay a dividend?
Not in its latest year — Andrew Yule & Company Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 4 of its last 13 reported fiscal years, so there is a history but no current dividend. — as of 11 September 2026.
Is Andrew Yule & Company Ltd overvalued?
On its own history, Andrew Yule & Company Ltd looks expensive: its P/E of 121.6× sits at the 86th percentile of its 10-year range (long-run median 52.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Andrew Yule & Company Ltd growing?
Yes — Andrew Yule & Company Ltd is growing: latest-quarter revenue +3.8% year on year, profit −111.6%, and the margin +25.9 pp at −23.4%. The earnings engine currently reads: improving — as of 11 September 2026.
How is Andrew Yule & Company Ltd performing?
Andrew Yule & Company Ltd is in a confirmed uptrend, 12 weeks in. Its latest quarter's revenue rose 3.8% and profit fell 111.6% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 11 September 2026.
Is Andrew Yule & Company Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 12 of stage 2), trading +2.1% versus its 200-day average and at 69% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Andrew Yule & Company Ltd beating the market?
Not lately — on a trailing-13-week view Andrew Yule & Company Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-09-04), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +19% against the NIFTY 500's +267% — behind the index over the full window. — as of 11 September 2026.
Will Andrew Yule & Company Ltd's share price go up?
This page publishes no price forecast for Andrew Yule & Company Ltd. What it measures instead: the share price is ₹26.1, the price is in a confirmed uptrend 12 weeks in. Its P/E of 121.6× sits at the 86th percentile of its own 10-year range. — as of 11 September 2026.
Who owns Andrew Yule & Company Ltd?
Promoters hold 89.3% of Andrew Yule & Company Ltd, foreign institutions 0.0%, domestic institutions 2.2% and the public 8.5% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Andrew Yule & Company Ltd have too much debt?
It is moderate — Andrew Yule & Company Ltd's debt-to-equity is 0.37, and operating profit covers the interest bill −13×. FY26 borrowings were ₹121 Cr against equity of ₹326 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is Andrew Yule & Company Ltd's capex?
Andrew Yule & Company Ltd spent ₹51.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹20.0 Cr, with ₹45.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Andrew Yule & Company Ltd's cash flow?
Andrew Yule & Company Ltd consumed ₹80.0 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−100 Cr). Reported profit that year was ₹−19.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Andrew Yule & Company Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 43% of Andrew Yule & Company Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−80.0 Cr against reported profit of ₹−19.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 11 September 2026.
Where is Andrew Yule & Company Ltd in its business cycle?
Andrew Yule & Company Ltd's FY26 operating margin was −32.0%, against a 13-year band of −32.0%–8.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran −23.4%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Andrew Yule & Company Ltd story?
The sharpest disagreement: profits are rising, but only 43% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Andrew Yule & Company Ltd a stock worth studying right now?
This is not investment advice. The machine read: Andrew Yule & Company Ltd is strength at full price. The numbers are improving — and a P/E at the 86th percentile of its own range says the market knows. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!